openPR Logo
Press release

Pharmaceutical Contract Manufacturing Global Market – Forecast To 2025

03-19-2019 04:09 PM CET | Health & Medicine

Press release from: IQ4I Research & Consultancy Pvt Ltd

Pharmaceutical Contract Manufacturing Global Market estimated to be worth $96 billion by 2025

Pharmaceutical Contract Manufacturing Global Market estimated to be worth $96 billion by 2025

Small molecule drugs are organic compounds with defined chemical structures and molecular weights typically ranging from 500 to 900 Daltons. Unlike biologics, these compounds can easily diffuse across cell membranes to reach intracellular sites and are designed to modulate a specific target that controls the biological processes associated with a specific disease.

In the last few years, though there is an increase in the growth of biologics market, small molecules continue to dominate the global therapeutics market. In 2018, FDA approved 59 drugs, of that 42 were small molecules and only 17 were biologics. Similarly, many small molecules are going off-patent, paving way for generics into the market through ANDA approval, 23 drugs received ANDA approval in 2018, creating a favorable opportunity for the Pharmaceutical contract manufacturers. During the period 2017-2018 475 companies filed type II DMFs and these filings indicate that majority of the companies are focusing in therapeutic areas like metabolic disorders (Type 2 diabetes), Musculoskeletal disorders (Psoriatic arthritis), Cancer (breast cancer), CNS (Major depressive disorder) and multiple fibrosis.

The global expenses for small molecule manufacturing is $xx billion, of that contract manufacturing occupies x.x% growing at a high single digit CAGR from 2018 to 2025 and expected to increase share during the forecast period. As estimated by IQ4I Research and Consultancy, the Pharmaceutical Contract Manufacturing Global Market is expected to grow at a high single digit CAGR to reach $95,904.9 million by 2025. The major factors driving the market includes patent expiration of small molecule drugs, increasing number of small molecules in clinical trials, increasing outsourcing by the pharmaceutical companies, CMOs investments to expand manufacturing facilities, rise in incidence of chronic and age-related diseases, rapid growth in oncology market, technological advancement like cryogenic and continuous flow manufacturing. However, contamination during manufacturing, side effects associated with small molecules, increasing shift towards biologics and stringent regulations are hindering the growth of the Pharmaceutical Contract Manufacturing market.

Even though, the CMO market witnessed some of the strategic acquisition and mergers by contract manufactures to expand their respective service portfolios, the market remained fragmented with the top-15 players in the sector only occupying ~10%-15% market share. Some of the contract manufacturing organizations (CMOs) are transforming into Contract development and manufacturing organization (CDMO) by offering end to end services, ranging from development activities including clinical trials to commercial scale production and regulatory filings. The pharmaceutical CMO’s estimated capacity is 43.3% of total pharmaceutical manufacturing volume. The capacity utilization of total CMO manufacturing volume during 2018 was estimated to be 65% and expected to grow at a mid single digit CAGR from 2018 to 2025 to reach 72% capacity utilization by 2025. In 2018, Global small molecule API production was estimated to be 350kt of which CMO production accounted for more than half.

The Pharmaceutical Contract Manufacturing global market is segmented based on the Product, Customer base, dosage forms, phase, and applications. Among Product, API Manufacturing holds the maximum revenue in 2018 and FDF Manufacturing is expected to grow at a strong single digit CAGR from 2018 to 2025, due to rising demand for FDF manufacturing, increase in controlled release dosage forms, oral dosage forms for the treatment of oncology and rise in generic injectables. Generics are the key driver of the contract manufacturing of API and FDF due to their cost advantage over branded drugs. API Manufacturing by customer base is further sub-segmented into Branded and Generic. Generic API manufacturing holds the maximum share in 2018 and expected to grow at a high single digit CAGR from 2018 to 2025, due to patent expirations of drugs, increase in government initiatives to use generic drugs, increasing ANDA approvals and expansion of generic API manufacturing facilities to meet global demand. FDF Manufacturing by customer base is further sub-segmented into a solid dosage form, semi-solid, liquid, gaseous dosage form, and injectable dosage forms. Among these solid dosage form holds the maximum share in 2018 and expected to grow at a mid single digit CAGR from 2018 to 2025, due to increase in oral solid dosage form as it is more convenient to patients than other dosage forms. However, the injectables are expected to grow at a double digit CAGR from 2018 to 2025, due to growth in use of generic injectables, increase use of injectable in chronic diseases and cancer.

Pharmaceutical contract manufacturing by phase is segmented into commercial manufacturing and clinical manufacturing. Commercial manufacturing holds the highest revenue in 2018 and expected to grow at a single digit CAGR from 2018 to 2025, due to huge demand for commercial API production, patent expiry increases commercial manufacturing of API and FDF and increase in outsourcing of generic APIs. Whereas, clinical manufacturing is expected to grow at a high single digit CAGR from 2018 to 2025, due to increase in the number of pipeline drugs where 55-60% of the APIs are synthetic API clinical phase 2 and 3 projects requiring cGMP facilities and increase in outsourcing by innovator pharma companies due to low cost manufacturing and shorter timelines. Also, clinical manufacturing play a significant role in securing client relationships that can lead to commercial scale manufacturing contracts.

Among the applications, Infectious diseases hold the highest revenue in 2018 and expected to grow at a high single digit CAGR from 2018 to 2025, due to increase in incidence of infectious diseases like hepatitis A, B and C and human immunodeficiency virus (HIV), increasing awareness about the infectious disease and newly emerging diseases like dengue fever, ebola virus, yellow fever, swine flu and avian flu, and chikungunya. Oncology is expected to grow at a strong single digit CAGR from 2018 to 2025, due to increase in the incidence of breast and lung cancer, increase in the usage of synthetic HPAPIs for cancer treatment, investment in new drug development and increasing regulatory approvals of oncology drugs. Some of the oncology drugs approved in 2018 are Venclexta (Venetoclax), Daurismo (glasdegib), Lorbrena (lorlatinib), duvelisib (Copiktra), apalutamide (Erleada).

Geographically, the North American region held the largest market share in 2018 wherein, the United States accounted for the highest revenue. This growth is driven by the high investments in cardiovascular and cancer research, growing demand for cancer API’s, constructive government reforms, availability of highest number of FDA approved manufacturing facilities and demand for generic drugs and adaptation of novel manufacturing technologies. Europe held the second largest share in 2018 where, Italy and Germany dominates the market, as Italy is the leader in API manufacturing mainly driven by exports, which represents 74% of the turnover and Germany is the leader in Finished dose formulation market.

Asia Pacific region is expected to grow with a high single digit CAGR from 2018 to 2025, due to the increase in the number of generic API production companies, rising affordability, enhanced life expectancy, improved standard of living and increase in population are driving the market. China and India are the low cost hubs for pharmaceutical contract manufacturing due to lower labor costs and capital expenditures. India has established itself as a significant player, especially in solid dosage form manufacturing for the large-scale production of generics for global markets. Availability of skilled workforce and lower labor cost are some of the factors propelling the rapid growth of the Asia-Pacific market.

The Pharmaceutical Contract Manufacturing global market is evolving with the increase in the number of API manufacturers. Many of the pharmaceutical companies without manufacturing and advanced capabilities of API and FDF tend to outsource manufacturing to CMOs. In pharma contract manufactuirng market CMOs are strategically enhansing their service capabilities by acquisition, investment, an expansion for providing access to new API and FDF manufacturing capacity and technologies. For instance, in January 2019, Cambrex Corporation has acquired Avista Pharma, a contract development, manufacturing, and testing organization (CDMO) for about $252 million, the facility adds pre-formulation, formulation, process development.

Small molecules still dominate the early and late stage pipeline development. In order to tap the opportunity several CMOs are investing in expansion. For instance, in September, 2018, Evonik Industries AG invested €36 million ($42 million) to expand its CMO capability in API manufacturing in U.S. and Europe. The company is enhancing the advanced technologies like high-potency API (HPAPI), and continuous processing at multiple manufacturing sites.

CMOs with advanced manufacturing technologies like continuous flow manufacturing, cryogenic process, high containment facility and capabilities to produce controlled substances and HPAPI drugs will attract the pharmaceutical companies to outsource API and FDF manufacturing. For instance, in August 2018, Nemus Bioscience, Inc. signed an agreement with AMRI for the development and manufacturing of Nemus’ proprietary cannabinoid-based active pharmaceutical ingredients (API) which is a controlled substance.

Major players in the Pharmaceutical Contact Manufacturing global market include Aenova Holding GMBH (Germany), Cambrex Corporation (U.S.), Abbvie Contract Manufacturing (U.S.), Patheon N.V. (Thermo Fisher Scientific) (Netherlands), Albany Molecular Research Inc. (U.S.), Famar S. A. (Greece), Lonza Group Ltd. (Switzerland), GlaxoSmithKline (U.K.), Pfizer CentreOne (U.S.), Wuxi STA pharmaceutical Co., Ltd. (China), Almac (U.K.) and Recipharm AB (Sweden).

For any further information please visit our website:
https://www.iq4i.com/reports-category/pharmaceuticals/r/185

IQ4I (Intelligence Quotient for Innovation) Research and Consultancy Pvt. Ltd. is a global strategy, consulting and a leading market research company. Our clients include leading businesses, investment banks, researchers and government agencies.

We are a team of highly qualified consultants and market researchers, committed to help clients make strategic decisions by providing relevant and firmly reliable market intelligence support. We enable our clients to identify the market opportunities with best-in-class market intelligence reports.

With world-class research capabilities, we deliver high-level strategically analyzed consulting and custom research assignments to our clients at a reasonable cost and time frame. With fact-based insights and accurate market forecasts, we enable our clients to understand and respond to the market dynamics with an edge over their competitors.

IQ4I Research & Consultancy Pvt. Ltd.
No 41/P4, Industrial Suburb
1st Floor, 3rd Main Road
1st Phase, KIADB Industrial Area
Peenya, Bangalore-560058

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pharmaceutical Contract Manufacturing Global Market – Forecast To 2025 here

News-ID: 1662213 • Views:

More Releases from IQ4I Research & Consultancy Pvt Ltd

IQ4I Research & Consultancy published a new report on
IQ4I Research & Consultancy published a new report on "Prefilled Syringes Global …
Prefilled syringes (PFS) are the sterile primary packaging systems or sealed containers that can also function as efficient drug delivery systems for the pre-loaded desired dose of parenteral pharmaceutical product. By engineering easier usability and improved patient experience into prefilled syringes, various prefilled syringe products have gained an unrivalled position as the most preferred or attractive container of choice for delivering injectable medical products in the market and have evolved
Cell Analysis Global Market estimated to be worth $39.3 billion by 2025
Cell Analysis Global Market estimated to be worth $39.3 billion by 2025
IQ4I Research & Consultancy published a new report on “Cell Analysis Global Market-Forecast to 2025”. Techniques: • Molecular approach  PCR  Sequencing  Microfluidics and Microarrays  Cell separation and isolation techniques • Image-Based Approach  Microscopy  Cytometry  High Content Screening  Spectrophotometry Products: • Consumables • Assay Kits • Microplates • Reagents • Cell culture consumables • Others • Instruments • Cell Counters • Cell Microarrays and Microfluidics • Liquid handling systems • Cytometers • High Content Screening • Microplate readers • PCR Instruments • Sequencing instruments • Spectrophotometers • Microscopes • Others Instruments • Software and Services Application: • Process of application • Cellular processes • Circulating Tumor Cells • Signal Transduction Pathway • Subpopulation Characterization • Drug and Candidate Screening • Single-cell analysis • Epigenetic target analysis • Field of Application  Forensic  Therapeutics  Cell Imaging  Biomarker research  Genomic analysis  Stem cell analysis  Diagnostics • Therapeutic Area of Application  Cancer
IQ4I Research & Consultancy published a new report on “Electrosurgical devices Global Market – Forecast To 2025”
IQ4I Research & Consultancy published a new report on “Electrosurgical devices …
Electrosurgery procedures employ devices where electrical energy is used to achieve a desired clinical effect in which a radio-frequency (RF), alternating current at a various voltage ranging from 200-10,000V is passed through the biological tissues to cut, coagulate, desiccate, or even to fuse tissue. Its benefit includes the ability to make precise cuts with limited blood loss during surgery. In electrosurgical procedures, the tissue is heated by an alternate current.
IQ4I Research & Consultancy published a new report on “Pharmaceutical Excipients Global Market – Forecast To 2025”
IQ4I Research & Consultancy published a new report on “Pharmaceutical Excipien …
Pharmaceutical Excipients are non-active substances combined with active pharmaceutical ingredient (API) during formulation to form a desired finished drug product, which helps in modulating solubility, bioavailability, stability and perform a wide range of functions. Pharmaceutical excipients are naturally derived or manufactured through semi-synthetic or synthetic modes. They are classified based on their physio-chemical characteristics in formulating different dosage forms based on nature of active ingredient and intended route of administration.

All 5 Releases


More Releases for API

API Testing Market (API Testing Software/Tools and API Testing Services), Global …
Application Programming interface (API) is the center of development, transferring data and logic across systems and applications. API is the connecting tissue between different systems or layers of an application. It enables communication and data exchange between two separate software systems. It contains a set of routines, protocols, and tools for building software applications APIs also specify how one software program should interact with other software programs. API testing tools
API Management Market Report 2018: Segmentation by Solution (API Portal, API Gat …
Global API Management market research report provides company profile for Akana, Inc. (U.S.), Apiary, Inc. (U.S.), Axway, Inc. (France), CA Technologies, Inc. (U.S.), Cloud Elements, Inc. (U.S.), Dell Boomi, Inc. (U.S.), DigitalML (U.S.), Fiorano Software, Inc. (U.S.), Google, Inc. (U.S.), Hewlett-Packard Enterprises Co. (U.S.), IBM Corporation (U.S.), Mashape Inc. (U.S.) and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical
Telecom API Market: OTT Service Providers Continue Cutting into Telecom API Prof …
The highly fragmented market of telecom API holds a staggering number of service providers and aggregators that are already offering their APIs to various telecom carriers. Alcatel Lucent, Apigee Corp., and Fortumo OU were the leading providers of telecom API from a global perspective in 2014. Telecom carriers have partnered with them and other prominent players in the past to launch APIs in the market. According to Transparency Market Research’s latest
Small Molecule API Market Growth Drivers 2018 | by Types Synthetic/Chemical API, …
Complete Study of Small Molecule API Market Research Report is added on MarketResearchFuture.com with Latest Advancement. Detail analysis on possible segments and sub segments of the Small Molecule API Market. Along with this regional analysis of the market which includes North America, Europe, Asia Pacific and Middle East and Africa. Global Small Molecule API Market – Overview Development in the small molecule API can be attributed due to the growth observed in
Parasoft Revolutionizes API Testing with New SOAtest Smart API Test Generator
Parasoft, the global leader in automated software testing, announced today the release of the Parasoft SOAtest Smart API Test Generator. This innovative technology uses artificial intelligence to convert manual UI tests into automated API tests, lowering the technical skills required to adopt API testing. By leaning on smart technology to perform the heavy lifting, it’s easier for organizations build and scale a comprehensive API testing strategy, which until now has
Open API Market - Cloud Computing Platforms Improve Scope of Telecom API Usage
The highly fragmented market of telecom API holds a staggering number of service providers and aggregators that are already offering their APIs to various telecom carriers. Alcatel Lucent, Apigee Corp., and Fortumo OU were the leading providers of telecom API from a global perspective in 2014. Telecom carriers have partnered with them and other prominent players in the past to launch APIs in the market. Obtain Report Details @ https://www.transparencymarketresearch.com/telecom-api-market.html According